Department of Clinical Pharmacology

Topiwala National Medical College & B. Y. L. Nair Charitable Hospital

Diabetes Mellitus

Type 2 Diabetes Mellitus

Obesity

Syndrome

Respiratory Distress Syndrome

Newborn Respiratory Distress Syndrome

Wet Macular Degeneration

Acute Lung Injury

Cytokine Release Syndrome

Overweight

Itolizumab

Orforglipron

Tirzepatide

ranibizumab

LY3298176

Lilly

Biocon

Lupin

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

This study will investigate the safety and efficacy of once daily oral treatment with orforglipron compared with placebo on body weight in adult participants with obesity or overweight and type 2 diabetes. The study will last about 77 weeks and may include up to 22 visits.

A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes

Topiwala National Medical College & B. Y. L. Nair Charitable Hospital | Department of Clinical Pharmacology

Site insights

Work at this site?

Active trials

A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2)

Trial sponsors